EGFR and non-small cell lung carcinoma: A phase I study was launched in April 2017 that aimed to find the recommended dose for TNO-155 in combination with EGFR inhibitor nazartinib in patients with advanced solid tumors, including EGFR mutant NSCLC and KRASG12-mutant NSCLC (NCT03114319).